Key Highlights: Implications: Dr. Reddy’s launch of Nivorz marks its entry into India’s biosimilar immuno‑oncology segment and adds a lower‑cost checkpoint inhibitor option across 12 appro...
Home / Nivolumab Biosimilar
Browsing Tag: Nivolumab Biosimilar
Featured Posts
1
The Algorithm Age: 10 AI Innovators Redrawing India’s Pharma Map
September 18, 20262
Dr. Reddy’s Signs License Agreement for Once-Yearly Lenacapavir
September 17, 20263
Alkem Launches NeuCeno in India for Partial-Onset Seizures
September 17, 2026